Indian stocks: Visit www.stage2stocks.com →

Femasys Inc.

Stage 4 · Declining · week 38

As of Oct 22, 2026, Femasys is in Stage 4, the downtrend phase, now in week 38 (since Jan 22, 2026). It closed at $1.56, 92.5% below its 52-week high and below its 200-day average, which is falling.

Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally. More about the company

$1.56
-5.45% today
$13.1M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is FEMY early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 16w
S4 23w
S4 39w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 6w → S1 3w → S2 8w → S3 10w → S2 12w → S3 6w → S4 16w → S1 6w → S4 10w → S1 1w → S2 11w → S3 4w → S4 23w → S1 10w → S4 39w current
Total tracked: 166 weeks across 15 stage runs.

FEMY among Medical Instruments & Supplies45th of 51 by relative strength

All 51 →
Stocks in Medical Instruments & Supplies ranked by relative strength, with stage and one-month change
#StockStageRS1M
1PLSEStage 2 · wk 3498+1.3%
2PDEXStage 2 · wk 3697−13.3%
3HBIOStage 2 · wk 1195+3.6%
4ATRCStage 2 · wk 1089−1.1%
5WSTStage 2 · wk 2482+4.8%
6BDXStage 2 · wk 1181+9.8%
7ICUIStage 3 · wk 181+3.1%
8OSURStage 3 · wk 875−4.8%
…45FEMYStage 4 · wk 388−39.5%
vs 52W High
-92.5%
$1.56 lo$20.80 hi
92.5% below 52W high, deep Stage 4 damage
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 38
1w13w26w
Week 38, extended decline
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-75.8%
200 DMA: $6.46 · sloping down
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
0.19x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-39.5%
3M
-58.0%
6M
-80.5%
YTD
-87.8%
1Y
-87.8%
Scan Membership
Breakout Watch
Latest: 2025-02-14
3 appearances in last 60 days. First seen: 2023-10-18.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S4
Wk 38 · Vol 0.19x
2026-10-21S4
Wk 38 · Vol 0.04x
2026-10-20S4
Wk 38 · Vol 0.04x
2026-10-19S4
Wk 38 · Vol 0.10x
2026-10-16S4
Wk 38 · Vol 0.06x
2026-10-15S4
Wk 37 · Vol 0.14x
2026-10-14S4
Wk 37 · Vol 0.23x
2026-10-13S4
Wk 37 · Vol 0.04x
2026-10-12S4
Wk 37 · Vol 0.07x
2026-10-09S4
Wk 37 · Vol 0.14x
2026-10-08S4
Wk 36 · Vol 0.07x
2026-10-07S4
Wk 36 · Vol 0.09x
Moving averages & range
50 DMA
$2.41
200 DMA
$6.46
52W High
$20.80
52W Low
$1.56
5D Low
$1.56
Resistance levels (recent highs)
20d High
$2.48
60d High
$3.43
120d High
$9.06
250d High
$20.80
Next resistance
+59.0%
to 20d High
ROE
-425.0%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 1.2

Femasys: quick answers

What stage is Femasys in?

As of Oct 22, 2026, Femasys (FEMY) is in Stage 4, the downtrend phase. It entered Stage 4 on Jan 22, 2026 and is in week 38. What the four stages mean

Is Femasys in an uptrend?

No. Femasys is in a Stage 4 downtrend. It trades 75.8% below its 200-day average, which is falling.

How far is Femasys from its 52-week high?

Femasys closed at $1.56 on Oct 22, 2026, 92.5% below its 52-week high of $20.80. Its 52-week low is $1.56.

How has Femasys performed over the past year?

As of Oct 22, 2026, Femasys is down 87.8% over the past year and down 87.8% so far in 2026.

Which sector and industry is Femasys in?

Femasys is in the Medical Instruments & Supplies industry, part of the Health Care sector.

About this companyHealth Care· Medical Instruments & Supplies

Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal patency; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; and FemCath, a cornual balloon catheter for selective tube evaluation. It also provides FemBloc, a non-surgical female permanent birth control solution. The company offers its products to gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.